Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp (NYSE American: ZOM) delivers innovative veterinary health solutions through advanced diagnostics and therapeutic technologies for companion animals and equines. This dedicated news hub provides investors and veterinary professionals with timely updates on corporate developments directly impacting animal healthcare innovation.
Access official press releases covering product launches, financial results, and strategic partnerships that shape Zomedica's position in veterinary medicine. Our curated collection ensures transparent access to regulatory filings, technology advancements, and market expansion initiatives without promotional bias.
Key updates on Zomedica's diagnostic platforms including TRUFORMA® assays, therapeutic device innovations, and clinical validation studies. Monitor operational milestones affecting veterinary practice efficiencies and animal health outcomes through verified corporate communications.
Bookmark this page for streamlined access to Zomedica's latest developments. Combine regular visits with professional financial advice when making investment or practice management decisions related to veterinary healthcare technologies.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has partnered with Qorvo Biotechnologies to develop three canine diagnostic assays for gastrointestinal issues: Cobalamin, cPL, and Folate. This initiative triggers a $2 million milestone payment under their agreement. These assays will enhance the TRUFORMA platform, enabling veterinarians to perform comprehensive gastrointestinal testing at the point-of-care, potentially improving diagnosis and treatment speed. The BAW sensor technology used in TRUFORMA promises laboratory-level accuracy, addressing a significant market need as GI conditions are common pet insurance claims.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) shares updates on its lead product, TRUFORMA, in a letter from Interim CEO Robert Cohen. With over US $50 million in cash, Zomedica aims to launch TRUFORMA with five assays, verified in partnership with Qorvo. The letter emphasizes rigorous validation and testing processes, and a hybrid sales model involving regional distributors and direct sales staff. Shareholder approval for a proposed reverse stock split is sought to comply with NYSE American requirements. Cohen expresses optimism about the company's future amidst ongoing challenges, including COVID-related adjustments.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) reported its second quarter financial results for the period ending June 30, 2020. The company posted a net loss of $5.3 million ($0.02 per share), an increase from $2.4 million in the same quarter last year. Research and development expenses surged 268%, totaling $3.9 million due to a milestone expense. However, cash reserves improved to $29.1 million from $510,586 at the end of 2019, aided by several equity offerings totaling $54 million. Zomedica aims to enhance its TRUFORMA™ diagnostic platform with ongoing validations and strong partnerships.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the appointment of Robert Cohen as a member of the Board of Directors, alongside Christopher Wolfenberg from Fasken Martineau DuMoulin LLP. Cohen joined Zomedica in June 2020, bringing over 20 years of experience in medical devices and biotechnology. The company is preparing for its Annual and Special Virtual-Only Meeting on September 25, 2020, where shareholders will ratify amendments to the by-laws facilitating electronic meetings and voting.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the resignation of Shameze Rampertab as Chief Financial Officer, effective August 14, 2020. Ann Cotter, CPA, currently the Vice President of Finance, will serve as interim CFO. Cotter has extensive experience in accounting and finance, having worked in various roles since August 2018. CEO Robert Cohen expressed gratitude for Rampertab's four years of service and looks forward to working with Cotter as the company prepares for the commercial release of its TRUFORMA™ platform, aimed at addressing unmet needs in veterinary diagnostics.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has successfully implemented the first remote installations of its TRUFORMA™ diagnostic device, facilitating validation testing with partner universities despite COVID-19 challenges. The device, designed for veterinary point-of-care diagnostics, recently completed verification for canine cortisol testing and plans to add more assays. Interim CEO Robert Cohen emphasizes the company's commitment to bringing TRUFORMA to market promptly, highlighting its innovative technology and the dedication of its team.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has priced a public offering of 187.5 million common shares and short-term warrants at $0.16 each, targeting approximately $30 million in gross proceeds. The offering is expected to close around July 7, 2020, pending customary conditions. Funds will primarily support the development of the TRUFORMA™ diagnostic platform and may also be used for potential repurchases of Series 1 Preferred Shares. H.C. Wainwright & Co. is the placement agent. The offering is not available to Canadian residents.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has announced a public offering of its common shares and warrants, all to be sold by the company. The offering is subject to market conditions, and its specific terms, including size and completion timing, are not guaranteed. Proceeds will primarily support development of the TRUFORMA™ diagnostic platform, including milestone payments under existing agreements and general corporate needs. H.C. Wainwright & Co. is the exclusive placement agent. The offering will not be available to Canadian residents.
Zomedica Pharmaceuticals Corp. has appointed Robert Cohen as its new Interim Chief Executive Officer, effective immediately. Cohen brings over 15 years of experience in the medical device and biotech industries, including a proven track record in launching medical devices. He will lead the completion and commercial launch of Zomedica's TRUFORMA™ diagnostic platform. Former interim CEO, Shameze Rampertab, remains as Chief Financial Officer. The company has raised over $30 million under Rampertab's leadership, supporting its development and commercialization efforts.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced a public offering of 133.3 million common shares and warrants at $0.15 each, aiming to raise approximately $20 million before expenses. The offering is set to close around May 29, 2020, and is managed by H.C. Wainwright & Co. Funds will be used for the development of Zomedica's TRUFORMA™ diagnostic platform and other general corporate purposes. The offering is detailed under SEC registration statement File No. 333-238322, and the securities are not available to Canadian residents.
